The Society of Hematologic Oncology (SOHO) was established as a non-profit corporation in 2012 with aims to promote worldwide research, education, prevention, clinical studies and optimal patient care in all aspects of hematologic malignancies and related disorders.
The phase I/II study was conducted at 15 sites in the United States and Canada. A total of 30 adults with AML or MDS at high risk of relapse received trem-cel as well as maintenance gemtuzumab ozogamicin, a CD33-targeting antibody, post-transplant.
Pirtobrutinib resulted in an 82.5% objective response rate in patients with Waldenström macroglobulinemia, and the ORR was 81.0% in those who previously received a Bruton’s
SOHO invites delegates and attendees to submit an abstract for a poster or oral presentation during the Fourteenth Annual Meeting of the Society of Hematologic Oncology (SOHO 2026). The deadline to submit an abstract is May 15, 2026.
Eight cash awards will be presented for best abstracts.
In this interview from the AACR Annual Meeting 2026, Shuguang Leng, MBBS, PhD, an associate professor at the University of New Mexico Comprehensive Cancer Center,
Selinexor was originally granted accelerated approval for this indication on June 22, 2020. The withdrawal does not affect the other approved indications for selinexor in multiple myeloma.
Meet Naval Daver, MD, a professor and director of the Leukemia Molecular Laboratory in the Department of Leukemia at the University of Texas MD Anderson Cancer Center.
To access the SOHO Career Center click the following link.
